SAGE THERAPEUTICS, INC.

(SAGE)
  Report
Real-time Estimate Cboe BZX  -  03:36 2022-08-18 pm EDT
42.90 USD   -0.51%
08/03Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating
MT
08/03Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Rating
MT
08/03Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Sage Therapeutics, Inc.
Sage Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. It has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. It targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. It has a portfolio of other compounds that target GABAA receptors, including SAGE-324.

Number of employees : 471 people.
Sales per Business
20202021Delta
Novel Medicines1 114.20100%6.31100% -99.43%
USD in Million
Sales per region
20202021Delta
United States1 114.20100%6.31100% -99.43%
USD in Million
Managers
Name Title Age Since
Barry Greene President, Chief Executive Officer & Director 57 2020
Kimi Iguchi Chief Financial Officer 58 2013
Albert Robichaud Chief Scientific Officer 60 2011
Amy Schacterle Senior VP-Research & Development Strategy - 2020
Matt Lasmanis Chief Technology & Innovation Officer - 2020
Helen Rubinstein Investor Relations Contact - -
Anne Marie Cook Secretary, Senior Vice President & General Counsel 59 2015
James Doherty Chief Development Officer - 2021
Jeffrey Jonas Director & Chief Innovation Officer 68 2020
Heinrich Schlieker Senior Vice President-Technical Operations - 2015
Members of the board
Name Title Age Since
Kevin Starr Chairman 58 2013
Steven Paul Independent Director 70 2014
James M. Frates Independent Director 53 2014
Michael F. Cola Independent Director 61 2014
Geno J. Germano Independent Director 60 2016
Elizabeth Barrett Independent Director 58 2019
George S. Golumbeski, Dr. Independent Director 64 2019
Jeffrey Jonas Director & Chief Innovation Officer 68 2020
Barry Greene President, Chief Executive Officer & Director 57 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 59,425,376 51,975,190 87.5% 3,033 0.0% 87.5%
Shareholders
NameEquities%
Wellington Management Co. LLP 6,995,000 11.8%
Biogen Inc. 6,241,473 10.6%
The Vanguard Group, Inc. 4,656,808 7.88%
Fidelity Management & Research Co. LLC 3,514,883 5.95%
Bellevue Asset Management AG 2,973,178 5.03%
SSgA Funds Management, Inc. 2,835,356 4.80%
T. Rowe Price Associates, Inc. (Investment Management) 2,158,504 3.65%
Artisan Partners LP 1,521,580 2.58%
OppenheimerFunds, Inc. 1,443,145 2.44%
BlackRock Fund Advisors 1,309,094 2.22%
Company contact information
SAGE Therapeutics, Inc.
215 1st Street
Cambridge, MA 02142

Phone : +1.617.299.8380
Fax : +1.617.299.8379
Web : http://www.sagerx.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Sage Therapeutics, Inc.